U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934889) titled 'Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma' on April 11.

Brief Summary: The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.

Study Start Date: April 07

Study Type: INTERVENTIONAL

Condition: Glioblastoma Gliosarcoma

Intervention: DRUG: ERAS-801

will be administered orally at the assigned dose once daily starting on Cycle 1 Day 1.

DRUG: ABBV-637

will be administered intravenously over one hour (+/- 10 min) once every 28 days on...